Arbitrators see less favourable treatment of Canadian pharma facilities, but accept US explanation; “effective means” legal obligation also scrutinized

You are not logged in. If you are a subscriber, please Login to access. If you are not a subscriber, you can contact us for a rate quote at Alternatively, you can sign up to receive free email headlines here.